Abstract
Donor Derived Cell Leukemia (DCL) is a rare complication of Hematopoietic Stem Cell Transplantation (HSCT).DCL represents a unique form of leukemogenesis in which donor cells become transformed or proliferate followingengraftment in a foreign host environment. We report a 58-year old patient with B-cell acute Lymphocytic leukemia whounderwent an allergenic HSCT from his Human Leukocyte Antigens (HLA)-matched sibling. Three months after HSCT,chromosomal analysis revealed a female karyotype with a (9;22) translocation. This was confirmed with Fluorescencein Situ Hybridization and polymerase chain reaction studies in the recipient and the donor confirming the transmissionof occult leukemia.
Highlights
Allergenic hematopoietic stem cell transplant (HSCT) is considered an effective treatment strategy for Acute Lymphoblastic Leukemia (ALL) especially in patients with high-risk features
Post HSCT, secondary leukemia/ myelodysplastic Syndrome (MDS) that is derived from donor cell origin develops, being designated donor cell leukemia (DCL)
DCL is a rare phenomenon, which was probably under-diagnosed for many years and may represent up to 5% of all leukemia relapses post- HSCT [1]
Summary
Allergenic hematopoietic stem cell transplant (HSCT) is considered an effective treatment strategy for Acute Lymphoblastic Leukemia (ALL) especially in patients with high-risk features. We present a patient who developed donor cell- derived Chronic Myeloid Leukemia (CML) three months after allergenic HSCT from a human leukocyte antigen (HLA)-matched related donor for ALL. FISH analysis using probes 9q34 (ABL), 11q23 (MLL), and 22q11.2 (BCR) was performed.
Sign-in/Register to view highlights & summary 
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call